{"filing":{"accession_number":"0001213900-26-081996","cik":"0002023016","ticker":"TTRX","company_name":"Turn Therapeutics Inc.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"ea0299413-8k_turn.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026081996/ea0299413-8k_turn.htm"},"events":[{"id":20929,"run_id":18850,"accession_number":"0001213900-26-081996","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Turn Therapeutics disclosed an updated investor presentation on July 28, 2026, detailing clinical trial progress for GX-03 (Phase 2 interim data for atopic dermatitis showing encouraging efficacy signals, upcoming Phase 3 initiation timelines) and pipeline expansion into onychomycosis and hidradenitis suppurativa. This is a material operational/strategic disclosure of clinical development milestones and product pipeline advancement, but does not fit the specific categories of earnings release, M\u0026A, executive changes, or other defined event types. The disclosure of Phase 2 interim efficacy data and Phase 3 readiness for a lead therapeutic candidate would affect a reasonable investor's assessment of the company's clinical progress and commercial prospects.","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20437,"accession_number":"0001213900-26-081996","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Turn Therapeutics disclosed an updated investor presentation on July 28, 2026, detailing clinical trial progress for GX-03 (Phase 2 interim data for atopic dermatitis showing encouraging efficacy signals, upcoming Phase 3 initiation timelines) and pipeline expansion into onychomycosis and hidradenitis suppurativa. This is a material operational/strategic disclosure of clinical development milestones and product pipeline advancement, but does not fit the specific categories of earnings release, M\u0026A, executive changes, or other defined event types. The disclosure of Phase 2 interim efficacy data and Phase 3 readiness for a lead therapeutic candidate would affect a reasonable investor's assessment of the company's clinical progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:06:47.561282+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20437,"accession_number":"0001213900-26-081996","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Turn Therapeutics disclosed an updated investor presentation on July 28, 2026, detailing clinical trial progress for GX-03 (Phase 2 interim data for atopic dermatitis showing encouraging efficacy signals, upcoming Phase 3 initiation timelines) and pipeline expansion into onychomycosis and hidradenitis suppurativa. This is a material operational/strategic disclosure of clinical development milestones and product pipeline advancement, but does not fit the specific categories of earnings release, M\u0026A, executive changes, or other defined event types. The disclosure of Phase 2 interim efficacy data and Phase 3 readiness for a lead therapeutic candidate would affect a reasonable investor's assessment of the company's clinical progress and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:06:47.561282+00:00","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-07-28"}]}